HIV clade B DNA vaccine (PENNVAX-B) - Inovio

Drug Profile

HIV clade B DNA vaccine (PENNVAX-B) - Inovio

Alternative Names: DNA vaccine for prevention of HIV clade B infection - Inovio; PENNVAX-B

Latest Information Update: 09 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals; University of Pennsylvania
  • Class AIDS vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 12 May 2014 Pharmacodynamics data from a phase I trial in HIV infections (in volunteers) released by Inovio Pharmaceuticals
  • 10 Jul 2013 Immunogenicity data from the HVTN 070 and HVTN 080 phase I trials in HIV-1 infections released by Inovio Pharmaceuticals
  • 08 Nov 2012 Inovio Pharmaceuticals completes a phase I trial in HIV-1 infections in USA (NCT01082692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top